Lilly follows fellow drugmaker Johnson & Johnson, who sued the Health and Human Services Department on Tuesday, accusing the ...

Oil prices fell on Friday on signs demand in China, the world's biggest crude importer, continues to underperform amid its ...

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...

The agency’s new guidelines are created to eliminate pharmaceutical company practices that minimize or distract consumers ...

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...

How can clinical trial participants be prevented from recording information inaccurately? One solution for pharmaceutical ...

Nearly 99% of people with prediabetes and obesity or overweight who took weekly tirzepatide injections remained diabetes-free ...

Investors continued to see multiple shades of light red as biotechs continued to struggle in the wake of the postelection ...

Shares of Hims & Hers slid after Amazon.com said it would offer cheap treatments for concerns like hair loss, skin care and ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.